# Tyligand

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tyligand

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.tyligand.com
- Total disclosed funding: $20M
- Latest round: Series A (Jul 8, 2023)
- Investors on record: 13

## About

Based in Shanghai, China and established in 2018, Tyligand is a medicial company that provides tumor immunotherapy drug. In January 2018, the firm raised seed funding from new investor Suzhou Yanying Investment Management. In July 2023, it raised series A+ funding led by new investor Ming Bioventures. Other returning investors Bohe Angel Fund, China Medical System Holdings, new investors Calor Capital, Harvest Capital, Shengdi Investment, and Taikun Fund also participated in the round. The round was part of a larger USD 20 million series A funding. Yantao Zhang, the co-founder and chairman of the company, was the Chief Scientist of Eli Lilly's Small Molecule Design and Development Department, the first Managing Director of Lilly China R&D Center, and Vice President of Lilly Global Collaborative Research and Development Asia Pacific. 

The company integrates unique scientific insights into target proteins and rich experience in medicinal chemistry, and the company is committed to the development of novel small molecule drugs for tumors and immune diseases. The company has established a unique antitumor molecular pipeline, with indications covering lung cancer, colorectal cancer, hormone-driven tumors, and a variety of solid tumors.

In the future, the company will promote the transformation of the company's pipeline to the clinical phase, including the Phase II clinical trial of Oralpristone in China, the preclinical research and IND application of 3 innovative molecules, and the compound optimization of several First-in-class research projects.

## Funding rounds

- Series A, Jul 8, 2023 — Harvest Capital, CMS Ventures, Calor Capital, Ming Bioventures, Bohe Angel Fund, Taikun Fund, Shengdi Investment
- Series A, May 20, 2021, $20M — Virtus Inspire Ventures, Yijing Investment, CMS Ventures
- Angel, May 31, 2020 — K2VC, MED-FINE Capital, Bohe Angel Fund, Oriza Holdings
- Seed, Jan 1, 2018 — Suzhou Yanying Investment Management

## Investors

- Suzhou Yanying Investment Management (https://capitalatlas.ai/funds/suzhou-yanying-investment-management) — Seed
- K2VC (https://capitalatlas.ai/funds/k2vc) — Angel
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Angel
- Bohe Angel Fund — Angel, Series A
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Angel
- Virtus Inspire Ventures (https://capitalatlas.ai/funds/virtus-inspire-ventures) — Series A
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series A
- CMS Ventures (https://capitalatlas.ai/funds/cms-ventures) — Series A
- Harvest Capital — Series A
- Calor Capital (https://capitalatlas.ai/funds/calor-capital) — Series A
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series A
- Taikun Fund — Series A
- Shengdi Investment — Series A